Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo.
Biochem Pharmacol. 2023 Oct;216:115769. doi: 10.1016/j.bcp.2023.115769. Epub 2023 Aug 25.
Biochem Pharmacol. 2023.
PMID: 37634597
Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo.
Zhang Y, Vagiannis D, Budagaga Y, Sabet Z, Hanke I, Rozkoš T, Hofman J.
Zhang Y, et al. Among authors: budagaga y.
Pharmaceutics. 2022 Nov 24;14(12):2595. doi: 10.3390/pharmaceutics14122595.
Pharmaceutics. 2022.
PMID: 36559089
Free PMC article.
Item in Clipboard
Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study.
Sabet Z, Vagiannis D, Budagaga Y, Zhang Y, Novotná E, Hanke I, Rozkoš T, Hofman J.
Sabet Z, et al. Among authors: budagaga y.
Int J Mol Sci. 2022 Nov 18;23(22):14338. doi: 10.3390/ijms232214338.
Int J Mol Sci. 2022.
PMID: 36430819
Free PMC article.
Item in Clipboard
Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.
Morell A, Budagaga Y, Vagiannis D, Zhang Y, Laštovičková L, Novotná E, Haddad A, Haddad M, Portillo R, Hofman J, Wsól V.
Morell A, et al. Among authors: budagaga y.
Arch Toxicol. 2022 Dec;96(12):3265-3277. doi: 10.1007/s00204-022-03359-2. Epub 2022 Aug 16.
Arch Toxicol. 2022.
PMID: 35972551
Item in Clipboard
Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo.
Zhang Y, Vagiannis D, Budagaga Y, Sabet Z, Hanke I, Rozkoš T, Hofman J.
Zhang Y, et al. Among authors: budagaga y.
Biochem Pharmacol. 2022 May;199:115009. doi: 10.1016/j.bcp.2022.115009. Epub 2022 Mar 18.
Biochem Pharmacol. 2022.
PMID: 35314165
Item in Clipboard
Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter.
Vagiannis D, Zhang Y, Budagaga Y, Novotna E, Skarka A, Kammerer S, Küpper JH, Hofman J.
Vagiannis D, et al. Among authors: budagaga y.
Toxicol Appl Pharmacol. 2022 Jan 1;434:115823. doi: 10.1016/j.taap.2021.115823. Epub 2021 Dec 9.
Toxicol Appl Pharmacol. 2022.
PMID: 34896433
Item in Clipboard
Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo.
Vagiannis D, Budagaga Y, Morell A, Zhang Y, Novotná E, Skarka A, Kammerer S, Küpper JH, Hanke I, Rozkoš T, Hofman J.
Vagiannis D, et al. Among authors: budagaga y.
Int J Mol Sci. 2021 Nov 3;22(21):11936. doi: 10.3390/ijms222111936.
Int J Mol Sci. 2021.
PMID: 34769363
Free PMC article.
Item in Clipboard
Cite
Cite